Objectives: The objective of this study was to define the natural genotypic variation of the HIV-1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer inhibitor (InSTI) resistance.
Introduction
HIV integrase is a key enzyme for retroviral replication and one of the main targets of modern HIV therapy. 1, 2 Integrase strand-transfer inhibitors (InSTIs) reached clinical practice in Europe in 2007-08, after proving their efficacy in antiretroviral treatment-naive and -experienced subjects. 3 -6 Virological failure (VF) to the firstgeneration InSTIs raltegravir and elvitegravir is associated with development of resistance through three mutually exclusive pathways characterized by one signature resistance mutation in the catalytic domain of the enzyme, i.e. Y143R/C, N155H or Q148K/R/H, alongside accessory mutations that improve viral fitness or further reduce InSTI susceptibility. 7 -10 The resistance profile of the secondgeneration InSTI dolutegravir is being defined, as few subjects developed VF in clinical trials and data from routine care are still scarce. Viruses with Q148K/R/H plus at least one additional mutation, however, may also affect susceptibility to dolutegravir. 11, 12 Based on the low genetic barrier of first-generation InSTIs and with the increasing use of them in clinical practice, surveillance of transmitted InSTI-resistant HIV will be a key to optimizing InSTI efficacy. Primary InSTI resistance is still rare. However, it has started to be reported 13, 14 and will likely increase in the coming years. In addition, up to 34% of published sequences, 56% of those obtained from recent HIV infection, 15 contain polymorphisms in the integrase, 16 which modulate InSTI resistance in particular to raltegravir and elvitegravir and are frequently observed in InSTI VF. In this study, we performed a systematic, representative description of the natural sequence variation of the integrase gene across Europe, before InSTI drugs were commercially available. We also aimed to clarify the chances that spontaneously generated InSTI-resistant mutants could be circulating as minority species and be missed by routine population sequencing approaches.
Methods
A sample of 300 subjects was randomly selected from 1950 individuals enrolled in the European SPREAD programme in 2006 -07, before InSTIs were introduced into routine clinical care in Europe. SPREAD is a prospective HIV-1 resistance surveillance programme that collects representative data on the spread of HIV-1 resistance among newly diagnosed patients from all risk groups in Europe. Ethics requirements were fulfilled according to the procedure described in the ethics committee contract. Additionally, written informed consent was obtained for each patient. Population sequencing of plasma HIV-1 was performed (ViroSeq w HIV-1 Genotyping System, Abbott; Trugene w HIV-1 Genotyping Kit, Siemens; or in-house methods) in laboratories that successfully participated in the SPREAD quality control (QC) programme for population sequencing. Samples from laboratories that did not participate in the integrase sequencing QC programme or did not successfully meet the QC criteria were tested by one of the qualified laboratories that passed the QC programme within the SPREAD network using the above-mentioned commercial or in-house Sanger sequencing methods. HIV subtypes were determined using Rega Subtyping Tool v2 based on pol sequence data. 17 To screen for circulating low-frequency InSTI-resistant mutants, ultradeep integrase sequencing was additionally attempted in 65 subjects randomly selected from those included in the population sequencing analyses, using a 454 FLX Genome Sequencer with Titanium chemistry and a 1% threshold for mutant detection. Sequences were analysed using the Roches's proprietary Amplicon Variant Analyser software (v2.7). Sample contamination was ruled out by similarity analysis both against a pNL4.3 reference sequence and by per-amplicon phylogenetic analysis of all sequences .1% within an ultradeep sequencing run. Given the lack of a widely accepted list of integrase mutations for surveillance, we first listed all substitutions relative to the reference sequence HXB2 (GenBank accession number K03455) according to their frequency in the patient population. We then evaluated which substitutions achieved an HIVdb score ≥10 to at least one InSTI, representing substitutions with potential impact on InSTI susceptibility. We also listed integrase mutations included in the IAS-USA list (July 2014 update). 'Signature mutations' were: Y143R/C/H, N155H and Q148K/R/H for raltegravir; T66I, E92Q, F121Y, S147G, Q148R and N155H for elvitegravir; and G140S and Q148H for dolutegravir.
Results
Samples were retrieved and successfully analysed by population sequencing in 278 out of the 300 (92.7%) subjects selected. The prevalence of transmitted drug resistance mutations found by Sanger sequencing for PIs, NRTIs and NNRTIs was 2.5%, 9.71% and 7.91%, respectively. No signature InSTI mutations were detected. By contrast, we observed integrase-associated mutations with an HIVdb score ≥10 in 11 (4.0%) patients (Table 1 and Table S1 , available as Supplementary data at JAC Online). Samples unsuccessfully processed had a median (IQR) number of copies/mL of 57 000 (13 212 -374 154) . The HIV subtype from (Table S2 ). Of these, mutation E157Q was found in five (8.9%) individuals, in two of them as a low-frequency variant. The following mutations were found in one subject each: H51Y, G163R, both as low-frequency variants (1.9; 2.6% in the virus population each); G163K as major variant (100% in the virus population); E157Q was detected at a 22.1% frequency in a subject with transmitted Q58E mutations in the protease and D67N and K219Q mutations in the reverse transcriptase. No integrase substitutions with an HIVdb score ≥10 were detected in the remaining five subjects with transmitted dual-class resistance.
Discussion
No signature InSTI resistance mutations were circulating in Europe before InSTI introduction, although potentially relevant polymorphisms could be observed. This study also indicated a limited utility of ultrasensitive genotyping for surveillance of InSTIresistant minority variants at present, which might change if the burden of transmitted InSTI resistance increases. Elvitegravir and raltegravir have a low genetic barrier to resistance and extensive overlap in their drug resistance profiles. 18 Raltegravir is often prescribed as salvage therapy to subjects with MDR HIV who could select for InSTI resistance, which could be transmitted to newly infected subjects. Dolutegravir has a higher genetic barrier to resistance than elvitegravir and raltegravir, but its long-term potency might be reduced in the presence of Q148R/H/K plus one or two additional mutations. As dolutegravir is also often prescribed as salvage ART, dolutegravir resistance might also evolve in European populations in the coming years. Continued surveillance of InSTI resistance in Europe is thus warranted, including periodic re-evaluations of the usefulness of ultrasensitive genotyping technologies, which nowadays allow faster monitoring of transmitted resistance, particularly with large sample sets.
Substitutions detected with at least some presumed impact on ART susceptibility (i.e. having an HIVdb score ≥10) were E157Q, G163R/K, L74M, T97A, E138A, S153F and R263K. E157Q is a polymorphic accessory mutation weakly selected in patients receiving raltegravir and selected in vitro by elvitegravir. G163R/K are nonpolymorphic mutations in all subtypes except F, often selected in patients receiving raltegravir. However, their effect on InSTIs has not yet been well studied. L74M is a polymorphic accessory mutation selected in patients receiving raltegravir, elvitegravir and dolutegravir, which does not reduce InSTI susceptibility unless it is found in combination with other InSTI resistance mutations. T97A is a polymorphic accessory mutation selected by raltegravir and elvitegravir that occurs in 1% -5% of viruses from untreated persons. Combined with Y143C/R, it markedly reduces raltegravir susceptibility, although it has minimal effect alone. E138A is a non-polymorphic accessory resistance mutation usually occurring in combination with Q148 mutations, selected in patients receiving raltegravir, elvitegravir and dolutegravir. It is associated with .100-fold reduction in raltegravir and elvitegravir susceptibility and up to 10-fold reduced dolutegravir susceptibility in combination with Q148. S153F is selected in vitro by dolutegravir and is a rare non-polymorphic mutation, reducing raltegravir and dolutegravir susceptibility by 2-fold and elvitegravir susceptibility by 4-fold. R263K is a non-polymorphic mutation selected in patients receiving raltegravir and dolutegravir and in vitro by elvitegravir and dolutegravir, reducing raltegravir, dolutegravir and elvitegravir susceptibility by 2-fold, 2-fold and 3-to 5-fold, respectively. 19, 20 Therefore, as long as transmitted InSTI resistance remains at negligible levels, there is no clinical need to perform integrase genotyping before initiating InSTI therapy. However, continued surveillance is key to informing clinicians and policymakers about when baseline genotyping should be systematically recommended. It is essential to perform integrase gene genotyping in subjects failing InSTI therapy, as new InSTIs with alternative resistance profiles are under development and subjects should not be kept on failing InSTI regimens.
In conclusion, no signature InSTI-resistant variants were circulating in Europe before introducing InSTIs. However, polymorphisms that could contribute to InSTI resistance were not rare. As InSTI use becomes more widespread, continuous surveillance of primary InSTI resistance is warranted. This study provides an extensive assessment of primary InSTI resistance based on a representative sample of the European epidemic and is a robust baseline comparator for future InSTI surveillance, which will be key to modelling the kinetics of InSTI resistance patterns of transmission in Europe in the coming years.
